Abstract

Streptococcus pneumoniae causes substantial mortality among children under 5-years-old worldwide. Polysaccharide conjugate vaccines (PCVs) are highly effective at reducing vaccine serotype disease, but emergence of non-vaccine serotypes and persistent nasopharyngeal carriage threaten this success. We investigated the hypothesis that following vaccine, adapted pneumococcal genotypes emerge with the potential for vaccine escape. We genome sequenced 2804 penumococcal isolates, collected 4-8 years after introduction of PCV13 in Blantyre, Malawi. We developed a pipeline to cluster the pneumococcal population based on metabolic core genes into “Metabolic genotypes” (MTs). We show that S. pneumoniae population genetics are characterised by emergence of MTs with distinct virulence and antimicrobial resistance (AMR) profiles. Preliminary in vitro and murine experiments revealed that representative isolates from emerging MTs differed in growth, haemolytic, epithelial infection, and murine colonisation characteristics. Our results suggest that in the context of PCV13 introduction, pneumococcal population dynamics had shifted, a phenomenon that could further undermine vaccine control and promote spread of AMR.

Pneumococcal vaccination has been shown to promote emergence of non-vaccine S. pneumoniae serotypes. Here, the authors use data from Malawi to investigate whether vaccine introduction also results in changes in metabolic, virulence, and antimicrobial resistance profiles of circulating strains.

Details

Title
The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi
Author
Obolski, Uri 1   VIAFID ORCID Logo  ; Swarthout, Todd D. 2   VIAFID ORCID Logo  ; Kalizang’oma, Akuzike 3 ; Mwalukomo, Thandie S. 4 ; Chan, Jia Mun 5   VIAFID ORCID Logo  ; Weight, Caroline M. 6   VIAFID ORCID Logo  ; Brown, Comfort 7 ; Cave, Rory 5 ; Cornick, Jen 8 ; Kamng’ona, Arox Wadson 4   VIAFID ORCID Logo  ; Msefula, Jacquline 4 ; Ercoli, Giuseppe 9   VIAFID ORCID Logo  ; Brown, Jeremy S. 9   VIAFID ORCID Logo  ; Lourenço, José 10   VIAFID ORCID Logo  ; Maiden, Martin C. 11   VIAFID ORCID Logo  ; French, Neil 12 ; Gupta, Sunetra 11   VIAFID ORCID Logo  ; Heyderman, Robert S. 13   VIAFID ORCID Logo 

 Tel Aviv University, Department of Epidemiology and Preventive Medicine, School of Public Health, Faculty of Medicine, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Tel Aviv University, Porter School of the Environment and Earth Sciences, Faculty of Exact Sciences, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.12136.37); University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201); University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands (GRID:grid.7692.a) (ISNI:0000 0000 9012 6352) 
 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.7692.a); University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201) 
 Kamuzu University of Health Sciences, Blantyre, Malawi (GRID:grid.517969.5) 
 University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201) 
 University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201); Lancaster University, Faculty of Health and Medicine, Biomedical and Life Sciences, Lancaster, United Kingdom (GRID:grid.9835.7) (ISNI:0000 0000 8190 6402); Lancaster University, Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster, United Kingdom (GRID:grid.9835.7) (ISNI:0000 0000 8190 6402) 
 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.9835.7) 
 Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.83440.3b); University of Liverpool, Clinical Infection, Microbiology and Immunology, Institute of Infection Veterinary & Ecological Science, Liverpool, United Kingdom (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470) 
 University College London, UCL Respiratory, Division of Medicine, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201) 
10  University of Oxford, Department of Zoology, Oxford, United Kingdom (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Biomedical Research Centre, Universidade Católica Portuguesa, Faculty of Medicine, Lisbon, Portugal (GRID:grid.7831.d) (ISNI:0000 0001 0410 653X) 
11  University of Oxford, Department of Zoology, Oxford, United Kingdom (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
12  University of Liverpool, Clinical Infection, Microbiology and Immunology, Institute of Infection Veterinary & Ecological Science, Liverpool, United Kingdom (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470) 
13  Malawi Liverpool Wellcome Programme, Blantyre, Malawi (GRID:grid.4991.5); University College London, Mucosal Pathogens Research Group, Research Department of Infection, Division of Infection & Immunity, London, United Kingdom (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201) 
Pages
7477
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2891099742
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.